Mendelian susceptibility to mycobacterial diseases

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:748
Who is this for?
Show terms as
16Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Mendelian susceptibility to mycobacterial diseases, often called MSMD, is a rare inherited immune disorder that makes people unusually vulnerable to infections caused by mycobacteria. Mycobacteria are a group of bacteria that includes the germ that causes tuberculosis (TB) as well as many related bacteria found in the environment, called nontuberculous mycobacteria (NTM). People with MSMD can also get seriously ill from weakened, vaccine-strain bacteria used in the BCG tuberculosis vaccine, which is harmless to most people. The immune system normally fights off these germs easily, but in MSMD, a key part of the immune defense — a communication pathway between immune cells involving proteins called interferon-gamma and interleukin-12 — does not work properly. The disease usually shows up in childhood, often after a BCG vaccination or after exposure to environmental mycobacteria. Symptoms include repeated or severe infections that are hard to treat, swollen lymph nodes, fever, weight loss, and lung problems. Some people also develop infections with Salmonella bacteria or certain viruses. The severity varies widely depending on which gene is affected and how severely it is disrupted. Treatment focuses on long-term antibiotics and antifungal or antiviral medicines to control infections. In some cases, interferon-gamma injections are used to boost the immune system. For the most severe forms, a bone marrow transplant (stem cell transplant) can be curative. Early diagnosis is critical because untreated infections can be life-threatening.

Also known as:

Key symptoms:

Severe or repeated infections with mycobacteria (including TB-related bacteria)Serious illness after BCG tuberculosis vaccinationSwollen lymph nodes, especially in the neck or armpitsPersistent feverUnexplained weight loss or poor weight gain in childrenChronic cough or lung infectionsSkin sores or abscesses that are slow to healBone infections (osteomyelitis)Repeated Salmonella infections in the gut or bloodstreamFatigue and general feeling of being unwellInfections that do not respond well to standard antibiotics

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event
Sep 2018

Arikayce: FDA approved

Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Mendelian susceptibility to mycobacterial diseases.

View clinical trials →

No actively recruiting trials found for Mendelian susceptibility to mycobacterial diseases at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Mendelian susceptibility to mycobacterial diseases community →

Specialists

16 foundView all specialists →
JC
Jean-Laurent Casanova
NEW YORK, NY
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication
DM
Davood Mansouri
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication
JB
Jacinta Bustamante
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication
MJ
Mahnaz Jamee
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication
MT
Miyuki Tsumura
Specialist
3 Mendelian susceptibility to mycobacterial diseases publications
SO
Satoshi Okada
Specialist
3 Mendelian susceptibility to mycobacterial diseases publications
KN
Kosuke Noma
Specialist
2 Mendelian susceptibility to mycobacterial diseases publications
YM
Yoko Mizoguchi
Specialist
2 Mendelian susceptibility to mycobacterial diseases publications
AK
Armin Khavandegar
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication
SM
Seyed Alireza Mahdaviani
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication
SA
Sarina Ansari
MIDLAND, TX
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication
SA
Saba Alijani
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication
NT
Nooshin Taherzadeh-Ghahfarrokhi
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication
PM
Paul Szabolcs, MD
Pittsburgh, Pennsylvania
Specialist

Rare Disease Specialist

PI on 7 active trials
FK
Fereshteh Khalili-Moghaddam
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication
MZ
Majid Zaki-Dizaji
Specialist
1 Mendelian susceptibility to mycobacterial diseases publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Mendelian susceptibility to mycobacterial diseases.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Mendelian susceptibility to mycobacterial diseasesForum →

No community posts yet. Be the first to share your experience with Mendelian susceptibility to mycobacterial diseases.

Start the conversation →

Latest news about Mendelian susceptibility to mycobacterial diseases

No recent news articles for Mendelian susceptibility to mycobacterial diseases.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which specific gene is causing my (or my child's) MSMD, and what does that mean for how severe the disease will be?,What long-term antibiotic or other medicines will be needed, and what side effects should I watch for?,Is interferon-gamma treatment an option for us, and how would it be given?,Should we consider a bone marrow transplant, and if so, when would be the right time?,Are other family members at risk, and should they be tested?,What vaccines are safe to give, and which ones must be avoided?,Are there any clinical trials or new treatments we should know about?

Common questions about Mendelian susceptibility to mycobacterial diseases

What is Mendelian susceptibility to mycobacterial diseases?

Mendelian susceptibility to mycobacterial diseases, often called MSMD, is a rare inherited immune disorder that makes people unusually vulnerable to infections caused by mycobacteria. Mycobacteria are a group of bacteria that includes the germ that causes tuberculosis (TB) as well as many related bacteria found in the environment, called nontuberculous mycobacteria (NTM). People with MSMD can also get seriously ill from weakened, vaccine-strain bacteria used in the BCG tuberculosis vaccine, which is harmless to most people. The immune system normally fights off these germs easily, but in MSMD,

At what age does Mendelian susceptibility to mycobacterial diseases typically begin?

Typical onset of Mendelian susceptibility to mycobacterial diseases is childhood. Age of onset can vary across affected individuals.

Which specialists treat Mendelian susceptibility to mycobacterial diseases?

16 specialists and care centers treating Mendelian susceptibility to mycobacterial diseases are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.